Werewolf Therapeutics (NASDAQ:HOWL) Trading Down 0.8% – Should You Sell?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shares fell 0.8% during mid-day trading on Friday . The stock traded as low as $0.63 and last traded at $0.6536. 198,728 shares were traded during mid-day trading, a decline of 52% from the average session volume of 417,370 shares. The stock had previously closed at $0.6590.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on HOWL shares. Bank of America dropped their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research report on Friday, December 19th. Finally, Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Stock Down 0.8%

The business’s fifty day moving average is $0.71 and its two-hundred day moving average is $1.15. The stock has a market cap of $31.73 million, a price-to-earnings ratio of -0.40 and a beta of 0.77. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Insiders Place Their Bets

In other news, major shareholder Ansbert Gadicke sold 88,802 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $0.98, for a total transaction of $87,025.96. Following the sale, the insider owned 5,168,303 shares of the company’s stock, valued at approximately $5,064,936.94. This represents a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bioventures 2014 L.P. Mpm sold 88,802 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $0.98, for a total value of $87,025.96. Following the completion of the sale, the insider owned 5,168,303 shares in the company, valued at approximately $5,064,936.94. The trade was a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,901,619 shares of company stock worth $2,505,134 over the last 90 days. Corporate insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. grew its position in shares of Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the last quarter. Susquehanna International Group LLP lifted its stake in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares during the last quarter. Citadel Advisors LLC acquired a new position in Werewolf Therapeutics during the 3rd quarter worth approximately $304,000. Finally, Vanguard Group Inc. increased its position in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.